1 McGuire WL, Clarck GM. Prognostic factors and treatment decision in node negative breast cancer. New Engl J Med 1992; 326: 1756-1761.
2 Hawkins RA. Prognostic factors: seeking a shft of ligth or getting lost in the woods?- a personal view from Sherwood Forest. Breast 1993; 2:125-129.
3 Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618-624.
4 Holland R, Hendriks JHCL, Verbeek ALM. et al. Extent, distribution, and mamografic/histological correlations of breast ductal carcinoma in situ. Lancet 1990; 335:519-522.
5 Page DL, Anderson TJ. Diagnostic histopathology of the breast. Churchill Livingstone. Edinburgh 1987.
6 Bellami COC, MacDonald C, Salter DM, Cetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993; 24:16-23.
7 Fisher ER, Constantino J, Fisher B, et al. Pathological findings from the National Surgical Adjuvant Breast project (NSABP) Protocol B-17: intraductal carcinoma (ductal carcinoma in situ). Cancer 1995; 75:1310-1319.
8 Poller DN, Silverstein M J, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new and simplifies histologicalclasification. Association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994; 7:257-262.
9 Holland R, Peterse JL, Millis R, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11:167-180.
10 EC Working Group on Breast Screening Pathology.
11 Tavassoli FA. Pathology of the Breast. Appleton & Lange. East Norwalk 1992.
12 Matsukuma A, Enjoji M, Toyoshima S. Ductal carcinoma of the breast. An analysis of the proportion of intraductal and invasive componenets. Pathol Res Prac 1991; 187:62-67.
13 Schnitt SJ, Connelly JL, Harris JR, et al. Pathologic predictor of early local recurrence in stage I and Stage II breast cancer treated by primary radiation therapy. Cancer 1984; 53:1049-1057.
14 Van Dongen JA, Fentiman IS, Harris JR. In situ breast cancer: the EORCT consensus meeting. Lancet 1989; 2:25-27.
15 Holland R, Connelly JL, Gelman R, et al. The presence of an extensive intraduct component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 1990; 8:113-118.
16 Jaquemier J, Kurtz JM, Amalric R, et al. An assessment of extensive intraductal component after breast-conserving therapy. Br J Cancer 1990; 61:873-876.
17 Veronesi U, Marubini E, Del Vechio M, etc. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995; 87:19-27.
18 Fisher ER, Sass R, Fisher B et al. Pathological findings fron the National Surgical Adjuvant Project for breast cancer (protocol nº 4). Discrimination for ten years failure. Cancer 1984; 53: 712-723.
19 Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24.740 breast cancer cases. Cancer 1989; 63:181-187.
20 Veronessi U, Galimberti V, Zurrida S, et al. Prognostic significance of number and level of axillary node metastasis in breast cancer. Breast 1993, 2:224-228.
21 Fisher ER, Palekar A, Rockette H, et al. Pathological findings fron the National Surgical Adjuvant Project for breast cancer (protocol nº 4). V. Significance of axillary nodal micro and macro metastases. Cancer 1978; 42:2032-2038.
22 International Breast Cancer Study Group. Prognosis importance of occult axillary lymph node micrometastases from breast carcinoma. Lancet 1990; 335:1565-1568.
23 Galea MH, Athanassiou E, Bell J, et al. Occult regional lymph node metastases from breast carcinoma: immunohistological detection with antibodies CAM 5.2 and NCR-11. J Pathol 1991; 165:221-227.
24 Mambo NC, Gallanger HS. Carcinoma of the breast. The prognostic significance of extranodal extension of axillary disease. Cancer 1977; 39:2280-2285.
25 Fisher ER, Greco M, Bufalino R et al. Pathological findings fron the National Surgical Adjuvant Project for breast cancer (protocol nº 4). III. The significance of extranodal extension of axillary metastases. Am J Clin Pathol 1976; 65:439-449.
26 Elston CW; Gresham GA, Rao GS, et al. The Cancer Research Campaign (Kings/Cambridge) trial for early breast cancer pathologic aspects. Br J Cancer 1982; 45:655-669.
27 Neville AM, Bettelheim R, Gelber RD, et al. Predicting treatment responsivesnees and prognosis in node negative breast cancer. J Clin Oncol 1992; 10:696-705.
28 Gallager HS, Martin JE, An orientation on the concept of minimal carcinoma. Cancer 1971; 28:1505-1507.
29 Hartman WH. Minimal breast cancer: an update. Cancer 1984; 53:681-684.0
30 Royal College of Radiologists: Quality Assurance Guidelines for Radiologists. NHS BSP Publications. 1990.
31 Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0MO-T1N1MO). Assessment of 644 patients with median follow up of 19 years. Surg Clin North Am 1990: 70:937-962.
32 Elston CW. Breast Pathology Course. Madrid 1996.
33 McDivitt RW, Boyce W, Gersell D.Tubular carcinoma of the breast. Am J Surg Pathol 1982; 6:401-411.
34 Page Dl, Dixon JM, Anderson TJ, et al. Invasive cribiforme carcinoma of the breast. Histopathol 1983; 7:525-526.
35 Dawson PJ, Ferguson DJ, Karrison T. The pathologic findings of breast cancer in patients surviving 25 years after radical mastectomy. Cancer 1982; 50:2131-2138.
36 Dixon JM, Page DL, anderson TJ, et al. Long term survivors after breast cancer. Br J Surg 1985; 72:445-448.
37 Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast a clincopathological study with a ten year follow-up. Cancer 1977; 40:1365-1385.
38 Fisher ER, Kenny JP, Sass R, et al. Medullary carcinoma of the breast revisited. Breast Cancer Res Treat 1990; 16:215-229.
39 Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long term follow-up. Histopathology 1992; 20:479-489.
40 Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (socalled lobular carcinoma in situ) of the breast. Cancer 1978; 42:737-767.
41 Dixon JM, Anderson TJ, Page DL, et al. Infiltrating lobular carcinoma of the breast. Histopathol 1982; 6: 149-161.
42 Greenhough RB. Varyng degrees of malignancy in cancer of the breast. J Cancer Res 1925; 9:149-161.
43 Patey DH, Scarff RW. The position of histology in the prognosis of carcinoma of the breast. Lancet 1928; 1:801-804.
44 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 1991; 19: 403-410.
45 Bloom HJG, Richardson WW: Histologica grading and prognosis in breast cancer A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11:359-377.
46 Dalton LW, Page DL, Dupont WD. Histologica grading of breast carcinoma: a reproducibility study. Cancer 1994; 73:2765-2770.
47 Robbins P, Pinder S, de Klerk N, et al. Histological grading of breast carcinomas. A study of interobserver agreement. Hum Pathol 1995; 26: 873-879.
48 Association of Directors of Anatomical and Surgical Pathology. Recomendation for the reporting in breast carcinoma. Hum Pathol 1996; 27:220-224.
49 Pereira H, Pinder SE, Sibbering DM, et al. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathol 1995; 27:219-226.
50 Sears HF, Janus C, Levy W, et al. Breast cancer without axillary metastases. Are there subpopulations? Cancer 1982; 50:1820-1827.
51 Roses DF, Bell DA, Fotte TJ, et al. Pathlogic predictors of recurrence in stage 1 (T1N0MO and T2N0MO) breast cancer. Am J Clin Pathol 1982; 78:817-820.
52 Örbo A, Stalsberg H, Kunde D. Topographic criteria in the diagnosis of tumor emboli in intramammary lymphatics. Cancer 1990; 66:972-977.
53 Pinder S, Ellis IO, O_Rourke S, et al. Pathological prognostic factors in breast cancer. III.Vascular invasion: relationship with recurrence and survival in a large series with long-term follow-up. Histopathol 1994; 24:41-47.
54 Saigo PE, Rosen PP. The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 1987; 59:51-54.
55 Fisher ER. Identification of risk factors by conventional pathological and some ancillary techniques in women with breast cancer. In: Ragaz and Ariel eds. High-risk breast cancer. Springer-Verlag. Heidelberg 1989. 233-251.
56 Battifora H, Metha P, Ahn Ch, Esteban JM. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standar?. Appl Immunohistochem 1993; 1:39-45.
57 Esteban JM, Kandalaft P, Mehta P, et al. Improvement of the cuantification of estrogen and progesterone receptors in paraffin-embedded tumors by image analysis. Am J Clin Pathol 1993; 99:32-38.
58 Allred DC. Should immunohistochemical examination replace biochemical receptor assay in breast cancer?. Am J Clin Pathol 1993; 99:1-3.
59 Nomura Y, Miura S, Koyama H, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 1992; 69:153-164.
60 Mascarel I, Soubeyran I, Mac Grogan J, et al. Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Concordance with biochemical assay and prognostic significance. Appl Immnohistochem 1995; 3:222-231.
61 Soubeyran I, Mac Grogan J, Mascarel I, et al. Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas. A correlative study of 942 cases. Appl Immnohistochem 1996; 4:219-227.
62 Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasisve breast carcinoma. N Engl J Med 1991; 324:1-8.
63 Weidner N, Folkman J., Pozza F, et al. Tumor angiogenesis: a new significant and independent prognodtic indicator in primary breast carcinoma. J Natl Cancer Inst 1992; 84:1875-18887.
64 Hall, NR, Fish DE, Hunt N, et al. Is the relationship between angiogenesis and metastasis in breast cancer real?. Surg Oncol 1992; 1:223-229.
65 Costello P, MacCann A, Carney DN, et al. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995; 26:11811184.
66 Axelsson K, Ljung BM, Moore DH, et al. Tumor angiogenesis as prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 1995; 87:997-1008.
67 Carter D, Elkins RC, Pipkin RD, et al. Relationship of necrosis and tumor border to lymph node metastases and 10 year survival in carcinoma of the breast. Am J Surg Pathol 1978; 2:39-46.
68 Parham DM, Hagen N, Brown RA.Simplified method of grading primary carcinomas of the breast. J Clin Pathol 1992; 45: 517-520.
69 Robertson AJ, Brown RA, Cree IA. Prognostic value of measurement of elastosis in breast carcinoma. J Clin Pathol 1981; 34:738-743.
70 Giri DD, Lonsdale RN, Dangerfield VJM, et al. Clinicopathologic significance of intratumoral variations in elastosis grades and the oestrogen receptor status of human breast cancers. J Pathol 1987; 151:297-303.
71 Muss HB, Thor AD, Berry D, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-1266.
72 Ellege RM, Gray R, Mansour E, et al. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemoterapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995; 87 1254-1256.
73 Goldhirsh A, Wood WC, Senn HJ, Glick JH, Gelber RD. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441-1445.
74 Galea MH, Blamey RW, Elston CW, et al. The Nottinghan Prognostic Index in primary breast cancer. Br Cancer Res Treat 1992; 22:187-191.
75 Brown JM, Benson EA, Jones M. Confirmation of a long-term prognostic index in breast cancer. Breast 1993; 2:144-147.
